Fisetin (3,3',4',7-tetrahydroxyflavone) is a naturally occurring flavonoid found in everyday foods like strawberries, apples, and persimmons — yet it has attracted serious attention from longevity researchers for a precise biological reason. Among ten flavonoids screened for senolytic activity, fisetin ranked as the most potent, reducing senescent cell burden across multiple tissues in preclinical models [1]. The field of senolytics — compounds that selectively eliminate dysfunctional "zombie cells" that accumulate with age — is still young, and fisetin sits at its frontier: mechanistically compelling, early in human trials, and not yet validated by large randomized controlled studies.
What Is Fisetin?
Fisetin belongs to the flavonol subclass of polyphenols, sharing structural features with quercetin and luteolin. It is found naturally in strawberries (the richest dietary source), apples, persimmons, grapes, onions, and cucumbers, though the concentrations achievable through diet alone are far below those used in research settings. As a supplement, it is typically sold in doses ranging from 100 mg to 500 mg per capsule.
What distinguishes fisetin within the polyphenol family is its selectivity for senescent cells. Unlike broad antioxidants that interact with a wide range of cellular targets, fisetin exploits a specific vulnerability in senescent cells: their dependence on anti-apoptotic survival proteins. This selective targeting is what defines a senolytic action, and it separates fisetin from general anti-inflammatory or antioxidant compounds [4].
Senescent cells are cells that have permanently stopped dividing — typically in response to DNA damage, oxidative stress, or telomere shortening. They resist programmed cell death while secreting a damaging cocktail of inflammatory cytokines, proteases, and growth factors collectively known as the senescence-associated secretory phenotype (SASP). As senescent cell burden increases with age, SASP-driven chronic inflammation is thought to contribute to tissue dysfunction, cardiovascular aging, metabolic disease, and neurodegeneration [1][4].
Fisetin was formally identified as a senotherapeutic in a landmark 2018 study by Yousefzadeh et al., which screened ten flavonoids in multiple experimental systems. It was the only compound to significantly reduce senescent cell markers across cell culture, human tissue explants, and live animal models, while also extending median and maximum lifespan when given late in life to aged wild-type mice . That combination of results — spanning multiple biological systems and including a lifespan endpoint — established fisetin as a priority compound for translational longevity research.
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
Related Articles
Longevity Science
Rapamycin for Anti-Aging: The Ultimate 2026 Review
Evidence-based rapamycin review covering mTOR mechanism, PEARL trial results, dosing protocols, side effects, and the gap between animal and human longevity data.
The core mechanism of fisetin's senolytic activity centers on the PI3K-Akt-BCL-2/BCL-xL signaling pathway. Senescent cells upregulate BCL-2 family anti-apoptotic proteins (primarily BCL-2 and BCL-xL) as a survival strategy, effectively blocking the normal cellular death signals that would otherwise eliminate them. Fisetin disrupts this pathway, selectively triggering apoptosis in senescent cells while leaving healthy cells largely unaffected [7].
Research using human adipose-derived stem cells (ADSCs) quantified the senescence-marker reductions achievable with fisetin at 50 µM: reactive oxygen species (ROS) fell by approximately 74 to 78%, senescence-associated beta-galactosidase (SA-β-gal) by 41 to 49%, and the chromatin condensation marker H3K9me3 by approximately 58% (all p < 0.001 to p < 0.0001) [10]. Critically, cells maintained their differentiation capacity after treatment, supporting the concept that fisetin clears dysfunctional cells without impairing the healthy stem cell pool [10].
Beyond direct senolysis, fisetin also suppresses the SASP. By reducing circulating levels of pro-inflammatory cytokines including IL-1β, IL-6, TNF-α, and CXCL12, fisetin may limit the systemic damage senescent cells cause even before they are fully eliminated [1][6]. In aged mouse arteries, this SASP suppression — specifically through the CXCL12 axis — restored endothelial-dependent dilation and reduced arterial stiffness, improvements confirmed to be causally linked to senescent cell removal using genetic controls [6].
Fisetin's pharmacokinetics shape how it is used in practice. The compound has poor water solubility and undergoes rapid hepatic metabolism, meaning systemic bioavailability after oral dosing is limited and variable [11]. This limitation is biologically significant: even when fisetin reaches target tissues at effective concentrations, the drug exposure window is short. However, this may actually align with the biology of senolysis. Because senescent cells take weeks to reaccumulate after clearance, an intermittent "hit-and-run" dosing strategy — taking fisetin for a brief period, then stopping — is thought to be both rational and sufficient. Animal studies support this view, with intermittent protocols (one week on, two weeks off) producing durable improvements in physical function and senescence markers [5][10].
Who Might Benefit from Fisetin?
Interest in fisetin spans several age-related conditions where senescent cell accumulation is thought to play a mechanistic role. Research suggests that individuals who may derive the most benefit are those with measurable senescent cell burden — a biological state that increases with chronological age, obesity, chronic metabolic disease, and prior cancer treatment [4].
In the context of type 2 diabetes, fisetin research has shown particular promise. A study using a diabetic mouse model found that fisetin reduced senescent endothelial cells in the aorta and attenuated both diabetes-related and natural aortic aging. When combined with metformin, fisetin produced superior vascular protection compared to metformin alone, raising the possibility of complementary mechanisms in patients already on standard metabolic therapy [7].
Fisetin is also under active investigation in acute and high-risk settings. The STOP-Sepsis trial (NCT05758246) is an ongoing Phase 2 randomized controlled trial enrolling 220 elderly patients (age over 65) with sepsis, testing whether fisetin at 20 mg/kg can reduce organ failure scores by promoting clearance of senescent immune cells [3]. Separately, the biological rationale for fisetin in COVID-19 severity among nursing home residents was the basis for an NIH-funded multicenter clinical trial, connecting senescent cell accumulation in aging to amplified inflammatory responses to infection [2].
Researchers have also identified a potential role in neurological conditions. Fisetin selectively inhibits amyloid-beta plaque-associated cholinesterases (AChE and BChE) in human Alzheimer's brain tissue without disrupting normal neural cholinesterases [12]. This suggests a dual mechanism relevant to Alzheimer's disease — senolytic clearance of senescent cells in the brain combined with preservation of normal cholinergic neurotransmission — though this remains a hypothesis requiring clinical investigation [12]. More broadly, review data identify neuroinflammation suppression and oxidative stress reduction as additional neuroprotective properties of fisetin across multiple preclinical neurological models [11].
What the Research Says
The preclinical case for fisetin is unusually strong for a dietary compound. The 2018 landmark study demonstrated lifespan extension in wild-type aged mice when fisetin was administered late in life, alongside reduced senescence markers across multiple tissues and decreased pro-inflammatory cytokines in human adipose tissue explants [1]. A subsequent 2025 study in aged mice found that intermittent fisetin supplementation improved frailty scores and grip strength to a degree statistically indistinguishable from genetic clearance of p16-positive senescent cells — a stringent comparison rarely made in pharmacological research [5].
Human data are more limited but are beginning to accumulate. The first published human pilot trial (n=10, 500 mg/day for one week per month over six months) produced mixed results: four of ten participants showed reductions in biological aging markers, five showed increases, and one showed no change. No adverse events were reported [8]. While the absence of harm is meaningful at this early stage, the heterogeneous efficacy response underscores that fisetin is not a uniform intervention — biological age responder status may depend on baseline senescent cell burden, individual metabolism, or bioavailability factors not captured in small pilots.
A longitudinal human study (n=19) investigated epigenetic age effects of a combined senolytic protocol. Participants receiving dasatinib plus quercetin (D+Q) showed significant epigenetic age acceleration and decreased telomere length at three and six months. Adding fisetin to the D+Q protocol (DQF arm) attenuated this effect, with changes in epigenetic age acceleration that were no longer statistically significant [9]. This suggests fisetin may have a moderating role in combined senolytic regimens, though the study lacked randomization and a placebo arm. A 2024 review by Mayo Clinic researchers synthesized early Phase I and Phase II human trial data, documenting decreases in SASP factors including IL-6 and CRP in initial human studies [4].
The overall evidence picture is one of strong mechanistic and preclinical foundations meeting early-stage human signals. No completed large randomized controlled trial has yet established fisetin's efficacy in humans for any indication. Ongoing trials in sepsis, frailty, osteoarthritis, and cardiovascular disease are expected to produce more definitive data in the coming years. Bioavailability remains a recognized translational barrier, with nanodelivery strategies including liposomes and nanoparticles under active exploration [11].
Side Effects and Safety
The human safety data available for fisetin are limited in scale but consistently reassuring. Across all completed human studies, including the pilot trial (n=10) using 500 mg/day for one week per month over six months, no serious adverse events have been reported [8]. The STOP-Sepsis trial protocol doses fisetin at 20 mg/kg in elderly ICU patients — approximately 1,400 mg for a 70 kg individual — and has been approved through regulatory review, reflecting acceptable preclinical safety at this dose range [3].
Preclinical data flag theoretical genotoxicity concerns at very high concentrations in cell culture models. These findings have not translated to documented harm at the doses studied in animals or humans, but they represent an area requiring further characterization [11]. The poor oral bioavailability of fisetin may actually limit systemic exposure to concentrations at which preclinical concerns arise, though this also limits therapeutic efficacy.
A practical safety consideration is drug interaction potential. Fisetin undergoes significant hepatic metabolism via CYP450 enzymes, creating theoretical interaction risks with medications that share these metabolic pathways. BCL-2 inhibitory activity raises theoretical caution in patients on chemotherapy agents. Formal drug-drug interaction studies in humans have not been conducted. Clinicians and researchers note that caution is warranted in patients on anticoagulants, immunosuppressants, or oncology treatments [4][11].
The intermittent, short-course dosing protocols used in research differ substantially from continuous daily supplementation. The biological rationale for intermittent dosing is that senescent cells take weeks to reaccumulate after clearance, meaning brief exposure windows are sufficient and prolonged continuous use may not confer additional benefit [5][10]. This pattern also limits cumulative exposure, which may reduce long-term safety uncertainty. Fisetin's complete safety profile in humans remains to be characterized through the larger ongoing randomized trials.
How to Get Started
Fisetin supplements are commercially available without a prescription, typically formulated as capsules with doses ranging from 100 mg to 500 mg. The dose used in the only completed human pilot study was 500 mg per day for one week each month over six months [8]. The STOP-Sepsis trial uses 20 mg/kg as an acute single or double dose in a clinical setting [3]. No standardized dosing protocol has been validated by a completed randomized controlled trial, and the gap between these two dose levels is substantial.
Food intake may influence bioavailability. Data from a fisetin-derived compound suggest that taking fisetin with a meal containing fat may increase systemic exposure by approximately 50% compared to fasting conditions. Given fisetin's already-limited oral bioavailability and rapid hepatic clearance, timing supplementation with food is a reasonable practical step based on current pharmacokinetic understanding [11].
The intermittent dosing pattern — taking fisetin for approximately one week, then pausing for two to three weeks before repeating — is supported by animal data and the mechanistic logic of senolytic biology [5][1]. Continuous daily use is not established as more effective than intermittent use, and intermittent protocols are what human studies have actually tested. Individuals considering fisetin should discuss its use with a healthcare provider, particularly those with existing medical conditions, those taking prescription medications, or those who are pregnant or breastfeeding, given the limited human safety data and theoretical interaction risks.
Research-grade monitoring approaches include biomarkers of senescent cell burden (p16 expression in circulating T-cells, IL-6, CRP, GDF-15) and epigenetic biological age clocks. However, none of these are validated clinical endpoints for monitoring fisetin response in routine practice. The heterogeneous response observed in the pilot trial [8] reinforces that tracking individual response through any means currently available remains exploratory.
Frequently Asked Questions
Q: Is fisetin the same as quercetin?
Fisetin and quercetin are both flavonols and share structural similarities, but they are distinct compounds with different potency profiles as senolytics. In the Yousefzadeh 2018 screening study, fisetin outperformed quercetin and eight other flavonoids in reducing senescent cell burden across multiple experimental systems [1]. Research also suggests quercetin and fisetin may have complementary or potentially synergistic effects when used together, though combined regimens require careful interpretation [9].
Q: How long does it take for fisetin to work?
Animal studies using intermittent protocols of one to two weeks showed improvements in senescence markers and physical function within a single treatment cycle [5]. Human pilot data used a six-month protocol of one week per month, making it difficult to isolate the time course of effect [8]. Current evidence does not support a clear answer for how quickly an individual human might notice any measurable change; the biology suggests weeks are needed for senescent cell burden to meaningfully decline after a course of treatment.
Q: Can fisetin be taken with metformin?
Preclinical research in a diabetic mouse model found that fisetin combined with metformin produced superior reductions in vascular senescent cell burden compared to metformin alone [7]. This is a mechanistically plausible finding given their different targets, but no human combination study has been completed. Individuals already taking metformin who are considering fisetin should consult their prescribing physician before combining these interventions.
Q: Does fisetin cross the blood-brain barrier?
Fisetin is lipophilic and is generally expected to have some CNS penetration based on its physicochemical properties. Preclinical studies have documented neuroprotective effects in neurological disease models, and selective inhibition of Alzheimer's-associated cholinesterases was demonstrated in human brain tissue in vitro [12]. However, direct measurement of fisetin's CNS penetration in living humans has not been published. This contrasts with the Phase 1 Alzheimer's trial using dasatinib, where blood-brain barrier penetration was confirmed by cerebrospinal fluid sampling [4].
Q: What is the main reason fisetin is not yet a standard longevity intervention?
The primary barriers are the absence of completed large randomized controlled trials in humans and the compound's poor oral bioavailability. The preclinical and early human evidence is promising but not yet sufficient to establish fisetin as an evidence-based intervention for any specific indication [4][11]. Ongoing trials across multiple conditions are expected to provide more definitive data.
References
Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. doi:10.1016/j.ebiom.2018.09.015. PMID: 30279143.
Verdoorn BP, Evans TK, Hanson GJ, et al. Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era. Journal of the American Geriatrics Society. 2021;69(11):3023-3033. doi:10.1111/jgs.17416. PMID: 34375437.
Silva M, Pinto J, Torres R, et al. Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multicenter, randomized, adaptive allocation clinical trial. Trials. 2024;25(1):685. doi:10.1186/s13063-024-08474-2. PMID: 39434114.
Tavenier J, Rasmussen LJH, Tchkonia T, Kirkland JL, et al. Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases. Mechanisms of Ageing and Development. 2024;221:111995. doi:10.1016/j.mad.2024.111995. PMID: 39384074.
Murray KO, Carmichael OT, Duggal NA, et al. Intermittent supplementation with fisetin improves physical function and decreases cellular senescence in skeletal muscle with aging: A comparison to genetic clearance of senescent cells and synthetic senolytic approaches. Aging Cell. 2025;24(3):e70114. doi:10.1111/acel.70114. PMID: 40437670.
Mahoney SA, Venkatasubramanian R, Darling JS, et al. Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence. Aging Cell. 2024;23(3):e14060. doi:10.1111/acel.14060. PMID: 38062873.
Ji XM, Liu YQ, Zhang DW, et al. Fisetin clears senescent cells through the Pi3k-Akt-Bcl-2/Bcl-xl pathway to alleviate diabetic aortic aging. Phytotherapy Research. 2025;39(4):1752-1765. doi:10.1002/ptr.8507. PMID: 40259678.
Lee E, Burns M. The effects of fisetin on reducing biological aging: A pilot study. Alternative Therapies in Health and Medicine. 2024;30(9):40-47. PMID: 39269340.
Lee E, Kim I, Choi J, et al. Exploring the effects of dasatinib, quercetin, and fisetin on DNA methylation clocks: A longitudinal study on senolytic interventions. Aging (Albany NY). 2024;16(5):4276-4299. doi:10.18632/aging.205581. PMID: 38393697.
Mullen M, Cicciarelli J, Alexander M, et al. Fisetin attenuates cellular senescence accumulation during culture expansion of human adipose-derived stem cells. Stem Cells. 2023;41(9):860-872. doi:10.1093/stmcls/sxad036. PMID: 37279940.
Elsallabi O, Patruno A, Pesce M, et al. Fisetin as a senotherapeutic agent: Biopharmaceutical properties and crosstalk between cell senescence and neuroprotection. Molecules. 2022;27(3):738. doi:10.3390/molecules27030738. PMID: 35164003.
Darvesh S, Walsh R, Kumar R, et al. Differential senolytic inhibition of normal versus Aβ-associated cholinesterases: Implications in aging and Alzheimer's disease. Aging (Albany NY). 2025;17(2):345-361. doi:10.18632/aging.206227. PMID: 40159237.
This article is for informational purposes only and does not constitute medical advice. GLP-1 medications and dietary supplements should only be used under the supervision of a licensed healthcare provider. Always consult your doctor before starting, stopping, or changing any treatment.
